69 research outputs found
Pharmacotherapy of Smoking Cessation
Tobacco use is the number one cause of preventable diseases in the United States. Smoking accounts for more than 400,000 deaths yearly and 30% of all cancer deaths. Primary care physicians have access to 70% of smokers, approximately 60% of whom are perceived to be in excellent health. Recent advances in the pharmacotherapy of nicotine addiction, including nicotine nasal spray, nicotine inhaler, bupropion hydrochloride, and over-the-counter transdermal nicotine patches, have increased the treatment options physicians can offer to smokers. Physicians, especially thosein primary care specialties, should familiarize themselves with these products to improve efforts to help their patients stop smoking. This article reviews scientific data on the efficacy of approved medications, benefits, adverse effects, and appropriate use of these products. We also discuss nicotine addiction and treatment for special populations, including women, ethnic minorities, light smokers, and patients with cardiovascular and pulmonary diseases
Barriers, control and identity in health information seeking among African American women
Qualitative research methods were used to examine the role of racial, cultural, and socio-economic group (i.e., communal) identities on perceptions of barriers and control related to traditional and internet resources for seeking health information. Eighteen lower income, African American women participated in training workshops on using the internet for health, followed by two focus groups. Transcripts were analyzed using standardized coding methods. Results demonstrated that participants perceived the internet as a tool for seeking health information, which they believed would empower them within formal healthcare settings. Participants invoked racial, cultural, and socio-economic identities when discussing barriers to seeking health information within healthcare systems and the internet. The findings indicate that the internet may be a valuable tool for accessing health information among lower income African American women if barriers are reduced. Recommendations are made that may assist health providers in improving health information seeking outcomes of African American women
Exploring cigarette use among male migrant workers in Nigeria
Background:
There is limited knowledge about the use of cigarettes by blacks outside the United States (U.S).
Nigeria creates an opportunity to explore smoking behaviours, smoking cessation (nicotine dependence) and
use of cigarettes in a country that has a large black population outside the U.S.
Methods:
We conducted three Focus Group Discussions (FGDs) involving twenty-four male migrant workers
who reported that they were current cigarette smokers. Interviews were audio-taped and transcribed.
Results:
Four major themes namely: reasons for initiating and continuing to smoke cigarettes, factors affecting
brand choice, barriers to quitting, effect of smoking mentholated cigarette brands were identified.
Conclusion:
This study provides insight into the use of mentholated and non-mentholated cigarettes and
suggests the need for further studies to explore smoking behavior among Nigerian
Smoking Characteristics of a Homeless Population
When addressing tobacco control and smoking cessation measures, the homeless have been perceived as a difficult to reach population. The purpose of this study was to examine the smoking characteristics of a homeless population. Data were derived from a larger study that examined smoking among inner-city residents. Homeless smokers (n=107) were compared with non-homeless smokers (n=491) on socio-demographics, smoking characteristics, motivation to quit, and smoking cessation experiences. Results showed that homeless smokers were more likely to be white, smoke more cigarettes per day, initiate smoking at a younger age, and have a longer smoking history. Knowledge about the risks of smoking and the benefits of quitting was equally high in both groups. Homeless smokers were less likely to be preparing to quit smoking compared to non-homeless smokers. These factors place homeless smokers at increased risk of tobacco-related diseases. Programs are needed to design and test effective cessation interventions for homeless smokers
Efficacy of brief motivational interviewing on smoking cessation at tuberculosis clinics in Tshwane, South Africa : a randomized controlled trial
BACKGROUND AND AIMS : Tuberculosis (TB) patients who smoke risk adverse TB outcomes and other long-term health
effects of smoking. This study aimed to determine the efficacy of brief motivational interviewing by lay health-care
workers (LHCWs) in assisting TB patients to quit smoking. DESIGN : Multi-centre two-group parallel individual
randomized controlled trial. SETTING : Six primary care tuberculosis clinics in a South African township.
PARTICIPANTS : Newly diagnosed adult TB patients identified as current smokers were randomized to brief motivational
interviewing by a LHCW (intervention group, n = 205) or brief smoking cessation advice from a TB nurse (control
group, n = 204). MEASUREMENTS : The primary outcome was self-reported sustained 6-month smoking abstinence.
Exhaled carbon monoxide (CO) testing was offered to about half the participants. Secondary outcomes were sustained
abstinence at 3 months; 7-day point prevalence abstinence at 1, 3 and 6 months; and quit attempts. Allocation was
concealed. Primary analysis relied on intention to treat. Multi-level analysis accounted for site heterogeneity of effect.
FINDINGS : Self-reported 6-month sustained abstinence was 21.5% for the intervention group versus 9.3% for the
control group [relative risk (RR) = 2.29, 95% confidence interval (CI) = 1.34, 3.92]. Biochemically verified 6-month
sustained abstinence was also higher in the intervention group (RR 2.21, 95% CI = 1.08, 4.51) for the 166 participants
who were offered carbon monoxide testing. Self-reported 3-month sustained abstinence was 25.4% for the
intervention group and 12.8% for the control group (RR = 1.98, 95% CI = 1.24, 3.18). CONCLUSIONS : Motivational
interviewing by lay counsellors to promote smoking cessation in tuberculosis patients in South Africa approximately
doubled sustained smoking abstinence for at least 6 months compared with brief advice alone.KNCV Tuberculosis Foundation (grant 12.402.2/MvdW/U.10.0696/cal), Global Bridges Health Care Alliance for Tobacco Dependence Treatment and the National Research Foundation of South Africa (grant no. 80843).http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1360-0443hb201
Adherence to Principles of Motivational Interviewing and Client Within-Session Behavior
The purpose of this study was to examine whether counselor adherence to Motivational Interviewing (MI) principles was associated with more productive within-session client behavior in a smoking cessation trial for African American smokers. For these analyses 89 baseline counseling sessions of the trial were audiotaped and coded using the Motivational Interviewing Skill Code (MISC). Counselor adherence indicators included a global subjective rating of MI adherence and the frequency of MI-consistent and MI-inconsistent counselor behaviors described in the MISC. Indicators of productive client behaviors included global subjective ratings of within-session client functioning and counselor-client interaction, as well as the frequency of statements by the client favorable toward changing behavior (“change talk”) and resistant regarding changing behavior (“resist-change talk”). Results provided support for the principles of MI. Counselor adherence indexed by both the global subjective rating and MI-consistent behavior frequency was significantly positively associated with global ratings of within-session client functioning and counselor-client interaction, as well as more change talk
Design, recruitment, and retention of African-American smokers in a pharmacokinetic study
<p>Abstract</p> <p>Background</p> <p>African-Americans remain underrepresented in clinical research despite experiencing a higher burden of disease compared to all other ethnic groups in the United States. The purpose of this article is to describe the study design and discuss strategies used to recruit and retain African-American smokers in a pharmacokinetic study.</p> <p>Methods</p> <p>The parent study was designed to evaluate the differences in the steady-state concentrations of bupropion and its three principal metabolites between African-American menthol and non-menthol cigarette smokers. Study participation consisted of four visits at a General Clinical Research Center (GCRC) over six weeks. After meeting telephone eligibility requirements, phone-eligible participants underwent additional screening during the first two GCRC visits. The last two visits (pharmacokinetic study phase) required repeated blood draws using an intravenous catheter over the course of 12 hours.</p> <p>Results</p> <p>Five hundred and fifteen African-American smokers completed telephone screening; 187 were phone-eligible and 92 were scheduled for the first GCRC visit. Of the 81 who attended the first visit, 48 individuals were enrolled in the pharmacokinetic study, and a total of 40 individuals completed the study (83% retention rate).</p> <p>Conclusions</p> <p>Although recruitment of African-American smokers into a non-treatment, pharmacokinetic study poses challenges, retention is feasible. The results provide valuable information for investigators embarking on non-treatment laboratory-based studies among minority populations.</p
Integrating smoking cessation and alcohol use treatment in homeless populations: study protocol for a randomized controlled trial
Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data
<p>Abstract</p> <p>Background</p> <p>African Americans experience significant tobacco-related health disparities despite the fact that over half of African American smokers are light smokers (use ≤10 cigarettes per day). African Americans have been under-represented in smoking cessation research, and few studies have evaluated treatment for light smokers. This paper describes the study design, measures, and baseline characteristics from <it>Kick It at Swope III </it>(KIS-III), the first treatment study of bupropion for African American light smokers.</p> <p>Methods</p> <p>Five hundred forty African American light smokers were randomly assigned to receive bupropion (150mg bid) (n = 270) or placebo (n = 270) for 7 weeks. All participants received written materials and health education counseling. Participants responded to survey items and provided blood samples for evaluation of phenotype and genotype of CYP2A6 and CYP2B6 enzymes involved in nicotine and bupropion metabolism. Primary outcome was cotinine-verified 7-day point prevalence smoking abstinence at Week 26 follow-up.</p> <p>Results</p> <p>Of 2,628 individuals screened, 540 were eligible, consented, and randomized to treatment. Participants had a mean age of 46.5 years and 66.1% were women. Participants smoked an average of 8.0 cigarettes per day, had a mean exhaled carbon monoxide of 16.4ppm (range 1-55) and a mean serum cotinine of 275.8ng/ml. The mean Fagerström Test for Nicotine Dependence was 3.2, and 72.2% of participants smoked within 30 minutes of waking. The average number of quit attempts in the past year was 3.7 and 24.2% reported using pharmacotherapy in their most recent quit attempt. Motivation and confidence to quit were high.</p> <p>Conclusion</p> <p>KIS-III is the first study designed to examine both nicotine and bupropion metabolism, evaluating CYP2A6 and CYP2B6 phenotype and genotype in conjunction with psychosocial factors, in the context of treatment of African American light smokers. Of 1629 smokers screened for study participation, only 18 (1.1%) were ineligible to participate in the study because they refused blood draws, demonstrating the feasibility of recruiting and enrolling African American light smokers into a clinical treatment trial involving biological data collection and genetic analyses. Future evaluation of individual factors associated with treatment outcome will contribute to advancing tailored tobacco use treatment with the goal of enhancing treatment and reducing health disparities for African American light smokers.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="URL">NCT00666978</a></p
- …